News articles about Concert Pharmaceuticals (NASDAQ:CNCE) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Concert Pharmaceuticals earned a news impact score of 0.12 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.6130971248974 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of NASDAQ CNCE traded up $0.17 during trading hours on Tuesday, hitting $20.30. 1,939 shares of the company’s stock were exchanged, compared to its average volume of 166,229. Concert Pharmaceuticals has a 1-year low of $11.88 and a 1-year high of $30.71. The stock has a market capitalization of $478.91 million, a PE ratio of 4.98 and a beta of 1.05.
Concert Pharmaceuticals (NASDAQ:CNCE) last posted its quarterly earnings data on Thursday, May 3rd. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.39. The business had revenue of $10.48 million during the quarter. Concert Pharmaceuticals had a negative return on equity of 23.57% and a net margin of 67.71%. sell-side analysts predict that Concert Pharmaceuticals will post -2.21 earnings per share for the current fiscal year.
CNCE has been the subject of several research analyst reports. Mizuho reissued a “hold” rating and set a $23.00 price objective on shares of Concert Pharmaceuticals in a research report on Tuesday, February 13th. ValuEngine raised Concert Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, April 3rd. Zacks Investment Research raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 12th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 price objective (up previously from $21.00) on shares of Concert Pharmaceuticals in a research report on Friday, March 2nd. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $26.50.
In other Concert Pharmaceuticals news, insider James V. Cassella sold 10,582 shares of the company’s stock in a transaction that occurred on Tuesday, April 17th. The stock was sold at an average price of $20.18, for a total value of $213,544.76. Following the completion of the transaction, the insider now owns 30,000 shares of the company’s stock, valued at approximately $605,400. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 9.40% of the company’s stock.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.